Answers are grounded in this paper and cite their sources.
Rabbit peritoneal polymorphonuclear leukocytes, elicited with glycogen, metabolized added [1-14C]arachidonic acid to the 5-lipoxygenase products 5-hydroxy-6,8,11,14-eicosatetraenoic acid and 5,12-dihydroxy-6,8,10,14-eicosatetraenoic acid (leukotriene B) and the 15-lipoxygenase product 15-hydroxy-5,8,11,13-eicosatetraenoic acid. These metabolites were isolated by high pressure liquid chromatography and converted to the trimethylsilyl-ether methyl ester derivatives, and the structures were confirmed by gas chromatography-mass spectrometry. When polymorphonuclear leukocytes were preincubated with 15-HETE (16 microM), the formation of 5-hydroxy-6,8,11,14-eicosatetraenoic acid and 5,12-dihydroxy-6,8,10,14-eicostatetraenoic acid from [1-14C]arachidonic acid was strongly suppressed. The concentration required for 50% inhibition of the 5-lipoxygenase pathway in these cells was approximately 6 microM, which is comparable to the concentrations (0.20 to 1.8 microM) of 15-hydroxy-5,8,11,13-eicosatetraenoic acid produced in incubations of polymorphonuclear leukocytes with arachidonic acid alone. Recent reports indicate that slow-reacting substance of anaphylaxis (leukotriene C/D) and chemotactic substance leukotriene B are arachidonic acid metabolites formed via the 5-lipoxygenase pathway. Our observations thus suggest that 15-hydroxy-5,8,11,13-eicosatetraenoic acid can regulate the formation of these vasoactive and inflammatory mediators intracellularly.
No takes yet. Share an insight, caveat, or question.
Vanderhoek et al. (1980) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: